Significance of IgM anti‐hepatitis D virus (HDV) in chronic HDV infection

Lau, Johnson Y. N.; Smith, Heather M.; Chaggar, Kanchan; Hansen, L. J.; Portmann, Bernard; Alexander, Graeme; Williams, Roger

doi:10.1002/jmv.1890330412

Cited by 18 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It requires the helper function of hepatitis B virus (HBV) for transmission and replication [2]. Clinically, HDV is usually defined as superinfection in the individuals with viral hepatitis B. HDV infections defined in Europe and in Turkey are usually associated with severe liver damage [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta

İspiroğlu

Bahçecıoğlu

Demirel

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chronic HDV. Methodology: A total of 47 patients who received Peg-IFNα therapy for at least one year were investigated. The patients were divided into three groups based on their response to treatment: sustained viral response (SVR) (32%), unresponsive (53%), and relapse (15%). The groups were compared in terms of age, gender, blood biochemistry (albumin, total bilirubin, lactic acid dehydrogenase, ALT, AST, ALP, GGT), complete blood count, HBeAg, HBsAg, HBV-DNA, HDV-RNA, IL28B genotypes (CC, CT, TT), and results of liver biopsy. Results: Regarding the investigation of IL28B genotype, the prevalence of CC, CT, and TT showed no difference among the three groups. In the SVR group, the prevalence of CC was 53%, CT was 47%, but there was no patient with TT. In the unresponsive group, prevalence of CC was 52%, CT was 32%, and TT was 16%. In the relapse group, prevalence of CC was 43%, CT was 57%, but there was no patient with TT genotype. No significant difference was found among the groups with sustained response, no response, and relapse in terms of CC and CT polymorphisms (p>0.05). Conclusions: No relationship was found between IL28B rs12979860 polymorphism and response to treatment and disease severity in patients with chronic HDV infection.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta

İspiroğlu

Bahçecıoğlu

Demirel

et al. 2017

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…1 Though the last 2 decades have seen a substantial decline in the circulation of HDV and the incidence of new forms of the disease in southern Europe, 2,3 there is still residual manifestation of the disease in patients infected years ago when HDV was endemic; these patients pose a difficult therapeutic challenge, as most have advanced disease and cirrhosis.…”

mentioning

confidence: 99%

Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta

et al. 2006

View full text Add to dashboard Cite

Therapy of chronic hepatitis delta with standard interferon therapy has met with limited efficacy. This study was designed to examine the efficacy and safety of peginterferon with or without ribavirin. Thirty-eight serum hepatitis B surface antigen-and HDV RNA-positive patients with alanine aminotransferase (ALT) more than 1.5 times the upper normal limit received peginterferon alpha-2b (1.5 g/kg) alone as monotherapy (n ‫؍‬ 16) or in combination with ribavirin (n ‫؍‬ 22), for 48 weeks. Thereafter, all the patients were maintained on peginterferon for 24 weeks and followed for 24 weeks off therapy. The primary end point studied was the virological and biochemical response at the end of follow-up. HDV RNA was determined by single or nested polymerase chain reaction assays. Twenty-seven patients (71%), 11 receiving monotherapy and 16 receiving the combination treatment, completed the follow-up. At the end of treatment, a virological response was observed in 3 of the patients treated with peginterferon (19%) and in 2 of the patients treated with combination therapy (9%), and a biochemical response was observed in 6 (37.5%) and 9 patients (41%), respectively. In nonresponders, ALT diminished from a mean of 174 ؎ 53 to 86 ؎ 41 IU/L. At the end of follow-up, serum HDV RNA was negative in 8 patients (21%), and a biochemical response was detected in 10 patients (26%). Treatment was discontinued in 25% of the patients, and dosing was modified in 58%. In conclusion, a prolonged course of peginterferon alpha-2b resulted in clearance of serum HDV RNA and ALT normalization in a fifth of patients with chronic hepatitis D, while ribavirin had no effect on the viral clearance rate. Overall tolerance of therapy was poor. (HEPATOLOGY 2006;44:713-720.)

show abstract

“…20 The role of IgM anti-HDV has been systematically studied in our Institute which showed only a weak correlation between serum IgM anti-HDV and both hepatic HDAg expression and inflammatory activities, indicating that IgM anti-HDV is not a good serum marker for active HDV replication nor active liver disease. 205 A recent study in our Institute showed that serum IgA anti-HAV was almost exclusively associated with chronic HDV infection and was an independent correlate of moderate/severe histological activity with a sensitivity of 82-6% and a specificity of 90.5%. 2027 There was, however, no correlation between serum IgA anti-HDV and expression of hepatic HDAg and serum transaminases.…”

Section: Pathogenesis Of Liver Diseasementioning

confidence: 89%